semaglutide alcohol use disorder
In a 12-week double-blind trial, semaglutide reduced daily alcohol units by 38%. The same study showed participants also lost an average of 4.7 kg, suggesting the drug can target both drinking and weight simultaneously. 38% reduction in daily alcohol units was observed in the semaglutide arm of the study.
tirzepatide
The biggest lie about semaglutide is that it is the safest GLP-1 drug, yet a 28.7% weight loss seen with tirzepatide shows a different risk-benefit balance. Recent EASO guidance shifts focus from just efficacy to side-effect profiles, prompting clinicians to reconsider first-line choices. Understanding the true safety landscape helps
digital phenotyping
Tirzepatide vs Semaglutide: Which GLP-1 Wins the Battle for Lean Body Mass and Real-World Weight Loss? In routine clinical practice, tirzepatide generally produces greater weight loss than semaglutide, but recent digital phenotyping data reveal a steeper decline in lean-body-mass with tirzepatide. The difference matters for patients who value muscle preservation
semaglutide side effects
In 2023, 82% of commuters using semaglutide reported that nausea resolved within 12 weeks, letting them keep their morning drive on schedule. Prescription weight-loss drugs can shift daily routines, and nausea is the most common side effect that can throw off a tight commute. Medical Disclaimer: This article is for
tirzepatide cost
A typical three-month course of prescription weight-loss drugs costs $12,000 to $14,000, and families can break that amount into monthly payments of $400-$550. I explain how insurance, timing, and discount programs turn a daunting bill into a manageable line item. Medical Disclaimer: This article is for informational
tirzepatide lean mass decline
In clinical data, tirzepatide users lost up to twice as much lean muscle as semaglutide users, a difference that can affect long-term health. While both drugs shrink body weight, the hidden impact on muscle mass is drawing attention from endocrinologists and patients alike. Medical Disclaimer: This article is for informational
orforglipron
Yes, moving to orforglipron within a defined window after stopping semaglutide or tirzepatide preserves most of the weight loss and prevents rebound. The key is a seamless handoff that maintains GLP-1 signaling while avoiding the hunger surge that typically follows. In 2023, 70% of patients who added orforglipron after discontinuing
Glpdrugs delivers practical drug facts, medication guides, and pharmaceutical news. Explore expert articles, actionable guides, and the latest trends.
Semaglutide can break post-bariatric weight-loss plateaus by delivering an average loss of 7.5 kg within 16 weeks, outperforming typical maintenance numbers. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Semaglutide: Breakthrough GLP-1
In clinical trials, tirzepatide caused nausea in about 32% of users during the first month, a higher rate than semaglutide’s 18%. Both drugs suppress appetite effectively, but the early gastrointestinal discomfort can influence adherence and choice of therapy. Medical Disclaimer: This article is for informational purposes only and does
In 2025, the EASO Commission positioned tirzepatide as the preferred first-line GLP-1 agent, citing superior weight-loss outcomes over semaglutide. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. tirzepatide EASO update Key Takeaways * Tirzepatide
In 2023, health plans that added semaglutide reported up to a 30% reduction in obesity-related claim costs. The drug’s ability to shrink excess weight while preserving lean tissue translates into fewer hospital stays, lower diabetes medication use, and reduced long-term expenditures. Medical Disclaimer: This article is for informational purposes
Semaglutide remains the first-line GLP-1 therapy in 2024, with tirzepatide reserved for patients who plateau, according to the latest EASO hierarchy. EASO’s 2024 clarification reshapes obesity treatment pathways, offering a clear algorithm that blends efficacy, safety, and cost. Below I walk through how each drug fits into modern protocols
40% More Lean Loss With Tirzepatide Vs Semaglutide Patients on tirzepatide lose about 40% more lean body mass than those on semaglutide, a difference that matters for long-term health. Digital phenotyping studies show this gap emerges within weeks, prompting clinicians to weigh muscle preservation when choosing a GLP-1 therapy. Medical
Family physicians can convert their clinic into a high-impact obesity treatment hub by integrating Wegovy through a clear five-step prescribing protocol and structured lifestyle support. In my practice, aligning medication with lifestyle coaching has turned routine visits into life-changing encounters, and the data show it saves lives. Medical Disclaimer: This
In head-to-head trials, 68% of women with PCOS achieved meaningful weight loss on tirzepatide versus 55% on semaglutide, making tirzepatide the current front-runner. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Semaglutide Dosing
Tirzepatide delivers lower cardiovascular risk per dollar spent, with a cost-adjusted risk of $2.45 per QALY versus $3.10 for semaglutide in 2024 analyses. This advantage stems from stronger weight loss and metabolic benefits, while both drugs remain priced as specialty therapies. Medical Disclaimer: This article is for informational
Yes, GLP-1 weight-loss drugs can shrink liver fat; a 2025 meta-analysis showed semaglutide 2.4 mg weekly reduced hepatic steatosis by up to 37% after 16 weeks, while also delivering robust weight loss. In my practice I have seen patients walk out of the clinic with lower BMI and clearer
Yes, WHO’s expanded coverage can lower diabetes medication expenses by up to 40%, especially when patients switch to fast-acting insulin and semaglutide. The policy streamlines procurement and leverages bulk pricing, delivering tangible savings for individuals and health systems. 40% of U.S. adults are classified as obese, driving demand
Tirzepatide generally costs more than semaglutide after insurance adjustments, with patients paying roughly $2,200 versus $1,300 per month on average. In 2024, tirzepatide’s list price averaged $3,400 per month, while semaglutide hovered around $1,300 per month, creating a price gap of over $2,000. Medical